{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-131064","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.817472+00:00","generated_at":"2026-05-28T23:36:25.238071+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity","bullets":["VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.","PK supports once-daily dosing; dose-dependent exposure reached steady-state after 7 days.","Increased target engagement biomarker HEXIM-1; inhibited Th17, Th1/myeloid, Th1/Tc inflammatory biomarkers.","No drug-drug interaction when co-administered with methotrexate, a common treatment for immune conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-131064","json":"https://secwatch.observer/filing/0001104659-24-131064.json","markdown":"https://secwatch.observer/filing/0001104659-24-131064.md","text":"https://secwatch.observer/filing/0001104659-24-131064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924131064/0001104659-24-131064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924131064/tm2431817d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:36:25.238071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}